Inhibikase Therapeutics IKT
NASDAQ IKT
$2.06 +0.04 (+1.98%)
At close: Sep 30, 2026 · 4:00 PM EDT

Inhibikase Therapeutics (IKT) Capital Expenditures (2022 - 2025)

Updated

Inhibikase Therapeutics (IKT) reported Capital Expenditures of $13,399 for FY2025.

Analysis

Inhibikase Therapeutics (IKT) Capital Expenditures (2022 - 2025) Analysis & Trends

  • Capital Expenditures has a three-year compound annual growth rate of -62.0% (FY2022 to FY2025).
  • According to Business Quant data, Capital Expenditures came in at $14,238 in FY2023 (-94.1%) and $243,255 in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capex (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 1.32 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 322.00 Mn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 893.00 Mn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -321.00 Mn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -763.00 Mn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 513.00 Mn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 140.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 533.00 Mn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 112.20 Mn
10 Inhibikase Therapeutics 359.62 Mn -225.86 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 13,399.00
Sep 30, 2022 200,166.00
API Access

Inhibikase Therapeutics Capital Expenditures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=capital-expenditures&ticker=IKT&period=max&api_key=YOUR_API_KEY